About
Carlos Balarezo appears to have been an operating executive in the longevity biotech ecosystem, most plausibly as CEO of Centagen circa 2018 based on a longevity-industry report. Current public evidence is sparse and somewhat ambiguous because separate web results also point to unrelated individuals with the same name, and Centagen's current team page no longer includes him.
Areas of interest
longevitybiotechstem cellsage-reversal therapeutics